Page 117 - 《中国药房》2023年24期
P. 117

国产帕利哌酮缓释片治疗稳定期精神分裂症的疗效与安全性



          李秀英 ,陈 莹 ,陈 宏 (1.山东省戴庄医院药学部,山东 济宁 272051;2.山东省戴庄医院精神科,山东
                                  2 #
                 1*
                          2
          济宁 272051)
          中图分类号  R971+.41;R969.4      文献标志码  A      文章编号  1001-0408(2023)24-3051-04
          DOI  10.6039/j.issn.1001-0408.2023.24.17

          摘  要  目的  探讨国产帕利哌酮缓释片替代原研帕利哌酮缓释片治疗稳定期精神分裂症的疗效和安全性。方法  收集2021年6
          月至2022年6月于山东省戴庄医院门诊就诊或住院且单一使用原研帕利哌酮缓释片治疗2个月及以上的精神分裂症患者65例,
          按随机数字表法分为国产组(33例)和原研组(32例);国产组患者换用相同剂量国产帕利哌酮缓释片治疗2个月,原研组患者继续
          使用原研药原剂量治疗2个月。分别于入组时和入组治疗1周末、1个月末和2个月末分别进行阳性和阴性症状量表(PANSS)、治
          疗伴发症状量表(TESS)评分,计算入组治疗2个月末的不良反应发生率;另外抽取静脉血检测空腹血糖、血脂指标(甘油三酯、总
          胆固醇、低密度脂蛋白、高密度脂蛋白、极低密度脂蛋白)、血清泌乳素水平和帕利哌酮血药浓度,计算帕利哌酮血药浓度与剂量的
          比值(C/D值),并行心电图检查。结果  国产组和原研组分别有31、30例患者完成试验。两组患者在入组时及入组治疗1周末、1
          个月末和2个月末的PANSS评分、TESS评分、C/D值比较,以及在入组时和入组治疗2个月末的空腹血糖、血脂指标、血清泌乳素水
          平比较,差异均无统计学意义(P>0.05),而各组患者在入组治疗1个月末和2个月末的PANSS评分与同组入组时比较均显著降低
         (P<0.01)。国产组和原研组的不良反应发生率分别为25.81%、30.00%,组间比较差异无统计学意义(P>0.05),且两组患者的心电
          图均无明显异常。结论  国产帕利哌酮缓释片可直接替代原研药治疗稳定期的精神分裂症,二者的临床疗效和安全性相当。
          关键词  帕利哌酮缓释片;精神分裂症;国产制剂;原研制剂;疗效;安全性

          Efficacy  and  safety  of  domestic  Paliperidone  extended-release  tablets  in  the  treatment  of  stable
          schizophrenia
                   1
                                            2
          LI Xiuying ,CHEN Ying ,CHEN Hong(1. Dept. of Pharmacy,Shandong Daizhuang Hospital, Shandong Jining
                                2
          272051, China;2. Dept. of Psychiatry,Shandong Daizhuang Hospital, Shandong Jining 272051, China)
          ABSTRACT   OBJECTIVE To investigate the efficacy and safety of domestic Paliperidone extended-release tablets as a substitute
          for  original  Paliperidone  extended-release  tablets  in  the  treatment  of  stable  schizophrenia.  METHODS  A  total  of  65  patients  with
          schizophrenia,  who  were  treated  with  single  original  Paliperidone  extended-release  release  tablets  for  2  months  or  more  in  the
          outpatient  or  inpatient  department  of  Shandong  Daizhuang  Hospital  from  June  2021  to  June  2022,  were  collected  and  randomly
          divided into the domestic group (33 cases) and the original group (32 cases). The domestic group was treated with the same dose
          of domestic Paliperidone extended-release tablets instead for 2 months, and the original group continued to use the previous dose of
          the  original  drug  for  2  months.  Positive  and  negative  syndrome  scale (PANSS)  and  treatment  emergent  symptom  scale (TESS)
          were used to evaluate the two groups at the time of enrollment and the end of 1 week, 1 month and 2 months after enrollment. The
          incidence  of  ADR  was  calculated  at  the  end  of  2  months  after  enrollment.  The  fasting  blood  glucose,  blood  lipid  indicators
         (triglyceride,  total  cholesterol,  low-density  lipoprotein,  high-density  lipoprotein,  very-low-density  lipoprotein),  serum  prolactin
          levels,  and  paliperidone  blood  concentration  were  determined  after  the  intravenous  blood  sample  was  collected.  The  ratio  of
          paliperidone  blood  concentration  to  dose (C/D  value)  was  calculated,  and  an  electrocardiogram  was  performed.  RESULTS  There
          were 31 and 30 patients in the domestic group and the original group who completed the trial, respectively. There were no statistical
          significances in PANSS score, TESS score or C/D value at the time of enrollment and the end of 1 week, 1 month and 2 months
          after enrollment; there were no statistical significances in the levels of fasting blood glucose, blood lipid or serum prolactin at the
          time of enrollment and at the end of 2 months after enrollment (P>0.05). PANSS scores of both groups significantly decreased at
          the  end  of  1  month  and  2  months  after  enrollment (P<0.01).  The  incidences  of  ADR  were  25.81%  in  the  domestic  group  and
          30.00%  in  the  original  group,  without  significant  difference (P>0.05),  and  there  were  no  significant  abnormalities  in  the
          electrocardiograms  of  the  two  groups.  CONCLUSIONS  Domestic  Paliperidone  extended-release  tablets  can  directly  replace  the
          original tablets in the treatment of stable schizophrenia, and their clinical efficacy and safety are comparable.
                                                             KEYWORDS     Paliperidone  extended-release  tablets;  schizo-
             *第一作者 副主任药师。研究方向:精神药理学。电话:0537-
                                                             phrenia;  domestic  preparation;  original  preparation;  efficacy;
          3165623。E-mail:550290515@qq.com
                                                             safety
             # 通信作者 主任医师,硕士。研究方向:临床精神病学。电话:
          0537-3165633。E-mail:chenhong1569@126.com


          中国药房  2023年第34卷第24期                                              China Pharmacy  2023 Vol. 34  No. 24    · 3051 ·
   112   113   114   115   116   117   118   119   120   121   122